Prognostic value of blood-based biomarkers in multiple sclerosis patients in the absence of clinical relapses or new MRI lesions.

ABSTRACT:

Background

In multiple sclerosis (MS), an increase in whole-brain lesion volume (LV) on MRI can be observed even in the absence of newly demarcated focal lesions or clinical relapses. However, it is unknown whether the presence of increasing LV alone is enough to justify changes in the therapeutic regimen. At this point, blood-based biomarkers may aid to identify patients at risk for progression.

Objective

To determine the prognostic value of blood-based biomarkers (serum neurofilament (sNfL) and serum glial fibrillary acidic protein (sGFAP)) on disability progression in MS patients without newly demarcated lesions or clinical relapses.

Design

Longitudinal cohort study.

Methods

In total, out of 291 MS patients who were retrospectively screened for this study, 1

SUBMITTER: Brummer T 

PROVIDER: S-EPMC12639232 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature